Rationale Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. The identification of ARDS phenotypes, based on focal or non-focal lung morphology, can be helpful to better target mechanical ventilation strategies of individual patients. Lung ultrasound (LUS) is a non-invasive tool that can accurately distinguish 'focal' from 'non-focal' lung morphology. The investigators hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients will lead to a reduction in 90-day mortality compared to conventional mechanical ventilation.
Objective The aim of this study is to determine if personalized mechanical ventilation based on lung morphology assessed by LUS leads to a reduced mortality compared to conventional mechanical ventilation in ARDS patients. Study design The PEGASUS study is an investigator-initiated multicenter randomized clinical trial (RCT) with a predefined feasibility and safety evaluation after a pilot phase. Study population This study will include 538 consecutively admitted invasively ventilated adult intensive care unit (ICU) patients with moderate or severe ARDS. There will be a predefined feasibility and safety evaluation after inclusion of the first 80 patients. Intervention Patients will receive a LUS exam within 12 hours after diagnosis of ARDS to classify lung morphology as focal or non-focal ARDS. Immediately after the LUS exam patients will be randomly assigned to the intervention group, with personalized mechanical ventilation, or the control group, in which patients will receive standard care. Main study parameters/endpoints The primary endpoint is all cause mortality at day 90 (diagnosis of ARDS considered as day 0). Secondary outcomes are mortality at 28 days, ventilator free days (VFD) at day 28, ICU length of stay, ICU mortality, hospital length of stay, hospital mortality and number of complications (VAP, pneumothorax and need for rescue therapy). After a pilot phase, feasibility of LUS, correct interpretation of LUS images and correct application of the intervention within the safe limits of mechanical ventilation is evaluated to inform a stop-go decision. Nature and extent of the burden and risks associated with participation, benefit and group relatedness Patient burden and risks are low as the ventilation methods in this study are already commonly used in ICU practice; the collection of general data from hospital charts and (electronic) medical records systems causes no harm to the patients; LUS is not uncomfortable.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
538
Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings: * Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O) * Tidal volume: 6 to 8 mL/kg predicted body weight (PBW) * Daily prone positioning LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol. Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings: * PEEP ≥ 15 cm H2O * Tidal volume: 4 to 6 mL/kg PBW * Daily recruitment maneuver
Patient who are randomized in the control group will receive standard care * Tidal volume: 6 mL/kg PBW * PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study * Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg
Chu-Brugmann
Brussels, Belgium
RECRUITINGBispebjerg Hospital
Copenhagen, Denmark
RECRUITINGNordsjaellands Hospital
Hillerød, Denmark
RECRUITINGEvaggelismos Hospital
Athens, Greece
RECRUITINGGalway University Hospitals
Galway, Ireland
RECRUITINGOspedale Generale Regionale F. Miulli
Acquaviva delle Fonti, Bari, Italy
RECRUITINGAzienda Ospedaliero Universitaria Consorziale Policlinico di Bari
Bari, Italy
RECRUITINGAmsterdam UMC, location VUmc
Amsterdam, North Holland, Netherlands
RECRUITINGAmsterdam UMC, location AMC
Amsterdam, North Holland, Netherlands
RECRUITINGCentralny Szpital Kliniczny MSWiA
Warsaw, Poland
RECRUITINGAll-cause mortality
Any death during ICU- or hospital-stay at day 90
Time frame: 90 days after inclusion
All-cause mortality
Any death during ICU- or hospital-stay at day 28
Time frame: 28 days after inclusion
Ventilator free days
Duration of ventilation in survivors
Time frame: 28 days after inclusion
ICU length of stay
Length of stay in the intensive care unit
Time frame: 90 days after inclusion
ICU mortality
Mortality in the ICU
Time frame: 90 days after inclusion
Hospital length of stay
Length of stay in the hospital
Time frame: 90 days after inclusion
Hospital mortality
Mortality in the hospital
Time frame: 90 days after inclusion
Number of patients with Complications
Ventilator associated pneumonia and pneumothorax
Time frame: 90 days after inclusion
Number of patients with Adjunctive therapies
Extracorporeal membrane oxygenation (ECMO), recruitment, prone position
Time frame: 90 days after inclusion
Number of patients with Rescue therapies
Inhaled vasodilators, airway pressure release ventilation
Time frame: 90 days after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.